<p>Equillium（納斯達克股票代碼：EQ - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場收盤後發佈其 2026 年第一季度財報。分析師預計 Equillium 本季度每股收益為（$0.04）。感興趣的人員被鼓勵訪問公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 12 日星期二東部時間下午 4:00 的電話會議的最新詳情。</p>
<ul>
<li>如果利率持續高位，3 個聰明的投資選擇</li>
</ul>
<p>Equillium（納斯達克股票代碼：EQ - 獲取免費報告）最近於 3 月 25 日星期三發佈了季度財報。該公司報告本季度每股收益為（$0.04），超出分析師一致預期的（$0.07）$0.03。分析師平均預計 Equillium 在當前財年每股收益為$0，在下一個財年每股收益也為$0。</p>
<h2>Equillium 價格表現</h2>
<p>EQ 股票在星期三開盤價為$2.07。該公司的 50 日移動平均價格為$1.99，200 日移動平均價格為$1.52。Equillium 的年內最低價為$0.27，年內最高價為$2.70。該股票的市值為 1.3089 億美元，市盈率為-4.14，貝塔值為 1.67。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>REITs 將在 2026 年反彈？7 個頂級選擇，利率下調在即</li>
</ul>
<p>多家研究公司對 EQ 發表了評論。Raymond James Financial 在 4 月 13 日星期一的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “強力買入” 評級，目標價為$6.00。Stifel Nicolaus 在 2 月 25 日星期三的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “買入” 評級，目標價為$5.00。Zacks Research 在 2 月 26 日星期四的研究報告中將 Equillium 的股票評級上調至 “持有”。Oppenheimer 在 4 月 23 日星期四的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “跑贏大盤” 評級，目標價為$7.00。最後，Cantor Fitzgerald 在 4 月 7 日星期二的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “增持” 評級，目標價為$10.00。一位股票研究分析師給予該股票 “強力買入” 評級，五位分析師給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Equillium 目前的共識評級為 “適度買入”，共識目標價為$7.67。</p>
<p><strong>獲取我們關於 Equillium 的最新研究報告</strong></p>
<h2>內部買賣情況</h2>
<ul>
<li>指引而非收益推動 Equinix 股票上漲</li>
</ul>
<p>在相關消息中，首席運營官 Christine Zedelmayer 於 2 月 19 日星期四出售了 185,937 股公司的股票。股票以平均價格$1.76 出售，總價值為$327,249.12。交易完成後，首席運營官持有 191,444 股公司股票，價值$336,941.44。此次交易使其持股減少了 49.27%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。過去三個月，內部人士共出售了 487,468 股公司股票，價值$990,467。17.84% 的股票由內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>多家對沖基金和其他機構投資者最近買賣了 EQ 的股票。Vanguard Group Inc.在第三季度將其在 Equillium 的持股增加了 59.4%。Vanguard Group Inc.目前擁有 1,313,946 股公司股票，價值$1,879,000，在上個季度又購買了 489,855 股。Two Sigma Investments LP 在第三季度獲得了 Equillium 的新頭寸，價值約$190,000。ADAR1 Capital Management LLC 在第三季度獲得了 Equillium 的新頭寸，價值約$7,951,000。Virtu Financial LLC 在第三季度將其在 Equillium 的持股增加了 133.4%。Virtu Financial LLC 目前擁有 23,779 股公司股票，價值$34,000，在上個季度又購買了 13,591 股。最後，Schonfeld Strategic Advisors LLC 在第三季度獲得了 Equillium 的新頭寸，價值約$178,000。機構投資者和對沖基金持有公司 27.05% 的股票。</p>
<h2>Equillium 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Equillium, Inc（納斯達克：EQ）是一家臨牀階段的生物製藥公司，專注於開發新型免疫療法以治療嚴重的自身免疫疾病並防止器官移植排斥。該公司的主要治療候選藥物 EQ001（itolizumab）是一種人源化單克隆抗體，通過靶向 CD6 受體來調節 T 細胞的激活。Equillium 的產品線還包括其他生物候選藥物，旨在解決急性移植物抗宿主病（GVHD）和狼瘡性腎炎等適應症。</p>
<p>Equillium 成立於 2015 年，總部位於加利福尼亞州拉荷亞，從 Biocon Limited 獲得了 itolizumab 的許可，利用該抗體在早期臨牀研究中的既定安全性。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Equillium</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVE"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Equillium 嗎？</h2>
<p>在考慮 Equillium 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Equillium 並不在名單上。</p>
<p>雖然 Equillium 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

IBBQ

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

<p>Equillium（納斯達克代碼：EQ）將於 5 月 13 日發佈 2026 年第一季度財報，分析師預計每股虧損為（$0.04）。該公司此前報告的每股虧損為（$0.04），超出預期。EQ 股票開盤價為$2.07，市值為 1.3089 億美元。分析師給予的共識評級為 “適度買入”，目標價為$7.67。最近的內部交易中，首席運營官 Christine Zedelmayer 出售了 185,937 股。機構投資者持有該股票的 27.05%，Vanguard 將其持股比例提高了 59.4%</p>

<p>Equillium (NASDAQ:EQ - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Equillium to post earnings of ($0.04) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Equillium（納斯達克股票代碼：EQ - 獲取免費報告）預計將在 2026 年 5 月 13 日星期三市場收盤後發佈其 2026 年第一季度財報。分析師預計 Equillium 本季度每股收益為（$0.04）。感興趣的人員被鼓勵訪問公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 12 日星期二東部時間下午 4:00 的電話會議的最新詳情。</p>
</div><ul>
<li>3 Smart Investments If Interest Rates Stay Higher for Longer</li>
</ul>
<div class="lb-trans"><ul>
<li>如果利率持續高位，3 個聰明的投資選擇</li>
</ul>
</div><p>Equillium (NASDAQ:EQ - Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. On average, analysts expect Equillium to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Equillium（納斯達克股票代碼：EQ - 獲取免費報告）最近於 3 月 25 日星期三發佈了季度財報。該公司報告本季度每股收益為（$0.04），超出分析師一致預期的（$0.07）$0.03。分析師平均預計 Equillium 在當前財年每股收益為$0，在下一個財年每股收益也為$0。</p>
</div><h2>Equillium Price Performance</h2>
<div class="lb-trans"><h2>Equillium 價格表現</h2>
</div><p>EQ stock opened at $2.07 on Wednesday. The company has a fifty day moving average price of $1.99 and a two-hundred day moving average price of $1.52. Equillium has a one year low of $0.27 and a one year high of $2.70. The stock has a market cap of $130.89 million, a price-to-earnings ratio of -4.14 and a beta of 1.67.</p>
<div class="lb-trans"><p>EQ 股票在星期三開盤價為$2.07。該公司的 50 日移動平均價格為$1.99，200 日移動平均價格為$1.52。Equillium 的年內最低價為$0.27，年內最高價為$2.70。該股票的市值為 1.3089 億美元，市盈率為-4.14，貝塔值為 1.67。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>REITs Set for a 2026 Rebound? 7 Top Picks as Rate Cuts Approach</li>
</ul>
<div class="lb-trans"><ul>
<li>REITs 將在 2026 年反彈？7 個頂級選擇，利率下調在即</li>
</ul>
</div><p>A number of research firms have commented on EQ. Raymond James Financial began coverage on shares of Equillium in a research report on Monday, April 13th. They set a &#34;strong-buy&#34; rating and a $6.00 price objective for the company. Stifel Nicolaus began coverage on shares of Equillium in a research report on Wednesday, February 25th. They set a &#34;buy&#34; rating and a $5.00 price objective for the company. Zacks Research raised shares of Equillium to a &#34;hold&#34; rating in a research report on Thursday, February 26th. Oppenheimer began coverage on shares of Equillium in a research report on Thursday, April 23rd. They set an &#34;outperform&#34; rating and a $7.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on shares of Equillium in a research report on Tuesday, April 7th. They set an &#34;overweight&#34; rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Equillium currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.67.</p>
<div class="lb-trans"><p>多家研究公司對 EQ 發表了評論。Raymond James Financial 在 4 月 13 日星期一的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “強力買入” 評級，目標價為$6.00。Stifel Nicolaus 在 2 月 25 日星期三的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “買入” 評級，目標價為$5.00。Zacks Research 在 2 月 26 日星期四的研究報告中將 Equillium 的股票評級上調至 “持有”。Oppenheimer 在 4 月 23 日星期四的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “跑贏大盤” 評級，目標價為$7.00。最後，Cantor Fitzgerald 在 4 月 7 日星期二的研究報告中開始覆蓋 Equillium 的股票。他們給予該公司 “增持” 評級，目標價為$10.00。一位股票研究分析師給予該股票 “強力買入” 評級，五位分析師給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Equillium 目前的共識評級為 “適度買入”，共識目標價為$7.67。</p>
</div><p><strong>Get Our Latest Research Report on Equillium</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Equillium 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><ul>
<li>Guidance, Not Earnings, Sends Equinix Stock Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>指引而非收益推動 Equinix 股票上漲</li>
</ul>
</div><p>In related news, COO Christine Zedelmayer sold 185,937 shares of the business's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the transaction, the chief operating officer owned 191,444 shares of the company's stock, valued at $336,941.44. The trade was a 49.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Insiders sold a total of 487,468 shares of company stock valued at $990,467 over the last three months. 17.84% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席運營官 Christine Zedelmayer 於 2 月 19 日星期四出售了 185,937 股公司的股票。股票以平均價格$1.76 出售，總價值為$327,249.12。交易完成後，首席運營官持有 191,444 股公司股票，價值$336,941.44。此次交易使其持股減少了 49.27%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。過去三個月，內部人士共出售了 487,468 股公司股票，價值$990,467。17.84% 的股票由內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of EQ. Vanguard Group Inc. raised its stake in Equillium by 59.4% in the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock valued at $1,879,000 after purchasing an additional 489,855 shares in the last quarter. Two Sigma Investments LP acquired a new position in Equillium in the third quarter valued at about $190,000. ADAR1 Capital Management LLC acquired a new position in Equillium in the third quarter valued at about $7,951,000. Virtu Financial LLC raised its stake in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock valued at $34,000 after purchasing an additional 13,591 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Equillium in the third quarter valued at about $178,000. Institutional investors and hedge funds own 27.05% of the company's stock.</p>
<div class="lb-trans"><p>多家對沖基金和其他機構投資者最近買賣了 EQ 的股票。Vanguard Group Inc.在第三季度將其在 Equillium 的持股增加了 59.4%。Vanguard Group Inc.目前擁有 1,313,946 股公司股票，價值$1,879,000，在上個季度又購買了 489,855 股。Two Sigma Investments LP 在第三季度獲得了 Equillium 的新頭寸，價值約$190,000。ADAR1 Capital Management LLC 在第三季度獲得了 Equillium 的新頭寸，價值約$7,951,000。Virtu Financial LLC 在第三季度將其在 Equillium 的持股增加了 133.4%。Virtu Financial LLC 目前擁有 23,779 股公司股票，價值$34,000，在上個季度又購買了 13,591 股。最後，Schonfeld Strategic Advisors LLC 在第三季度獲得了 Equillium 的新頭寸，價值約$178,000。機構投資者和對沖基金持有公司 27.05% 的股票。</p>
</div><h2>Equillium Company Profile</h2>
<div class="lb-trans"><h2>Equillium 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.</p>
<div class="lb-trans"><p>Equillium, Inc（納斯達克：EQ）是一家臨牀階段的生物製藥公司，專注於開發新型免疫療法以治療嚴重的自身免疫疾病並防止器官移植排斥。該公司的主要治療候選藥物 EQ001（itolizumab）是一種人源化單克隆抗體，通過靶向 CD6 受體來調節 T 細胞的激活。Equillium 的產品線還包括其他生物候選藥物，旨在解決急性移植物抗宿主病（GVHD）和狼瘡性腎炎等適應症。</p>
</div><p>Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.</p>
<div class="lb-trans"><p>Equillium 成立於 2015 年，總部位於加利福尼亞州拉荷亞，從 Biocon Limited 獲得了 itolizumab 的許可，利用該抗體在早期臨牀研究中的既定安全性。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Equillium</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Equillium</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVE" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=EQ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Equillium Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Equillium 嗎？</h2>
</div><p>Before you consider Equillium, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Equillium 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equillium wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Equillium 並不在名單上。</p>
</div><p>While Equillium currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Equillium 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Equillium (EQ) 預計將在週三發佈財報